You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Use of High-Risk Medications in the Elderly

Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported:

a. Percentage of patients who were ordered at least one high-risk medication

b. Percentage of patients who were ordered at least two different high-risk medications.

Date Reviewed: November 19, 2017

Measure Info

MIPS 238NQF 0022CMS 238NQF Endorsed
Measure Type: 
Process
Measure Steward: 
National Committee for Quality Assurance
Clinical Topic Area: 
Care Coordination
Geriatrics

Care Setting: 
Outpatient
Data Source: 
Claims
Registry

ACP does not support QPP measure 238: "Use of High-Risk Medications in the Elderly." While it is clinically important to monitor high-risk medications in elderly adults, implementation may result in underuse of clinically appropriate pharmacotherapy in adults aged > 65 years. Furthermore, developers cite the controversial American Geriatrics Society Beers Criteria to form the basis of the measure, which is based on expert opinion as opposed to high-quality evidence. Moreover, we note several issues with the measure specifications. First, the denominator may inaccurately define “elderly adults” as > 65 years of age. Developers should consider revising the specifications to include a more appropriate definition that would classify “elderly adults” according to mental and functional status or increase the denominator threshold to > 80 years of age. Second, the denominator specifications do not stratify patients into well-defined risk groups. It’s conceivable for some patients 66 years and older to tolerate high risk medications as appropriate treatment. Third, the measure specifies medications that are not presumed to be high risk in all elderly adults (e.g., acetaminophen), and fourth, the specifications do not include exclusion criteria for patient preference. Finally, while this measure is appropriate for health plan-level assessment, individual clinicians may encounter interoperability barriers to patient information access.